J Korean Med Assoc.  2011 May;54(5):530-536. 10.5124/jkma.2011.54.5.530.

Frequently used antiviral agents in the clinical environment

• Han S
• Yim DS

• KMID: 2190715
• DOI: http://doi.org/10.5124/jkma.2011.54.5.530

Abstract

More than 60 antiviral agents for various infectious diseases such as herpes, hepatitis, influenza, and AIDS are currently prescribed worldwide. Among the viral infections, hepatitis B and influenza are those frequently seen in primary care situations in Korea. This review discusses the anti-hepatitis B (HBV) drugs entecavir and adefovir, and the anti-influenza drugs oseltamivir and zanamivir. In addition, the pharmacology and therapeutic guidance suggested by the Korean Association for the Study of the Liver were reviewed for entecavir and adepovir, the most frequently prescribed anti-HBV drugs. For influenza, oseltamivir is commonly used despite debates on neuropsychiatric safety issues and zanamivir may be used when an inhalation form is necessary. Although currently used drugs show considerable clinical efficacy, efforts to optimize their use and further research to find new molecules that may overcome their limitations are necessary.

Keyword

Antiviral agent; Hepatitis B; Influenza

MeSH Terms

Adenine
Antiviral Agents
Communicable Diseases
Guanine
Hepatitis
Hepatitis B
Influenza, Human
Inhalation
Korea
Liver
Organophosphonates
Oseltamivir
Primary Health Care
Zanamivir
Adenine
Antiviral Agents
Guanine
Organophosphonates
Oseltamivir
Zanamivir

Reference

1. Safrin S. Katzung BG, Masters SB, Trevor AJ, editors. Antiviral agents. Basic & clinical pharmacology. 2009. New York: McGraw-Hill Medical;845–876.

2. Lee KS, Kim DJ. Guideline Committee of the Korean Association for the Study of the Liver. Management of chronic hepatitis B. Korean J Hepatol. 2007. 13:447–488.

3. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010. 52:176–182.

4. Lee CS. The diagnosis and treatment of influenza. J Korean Med Assoc. 2010. 53:43–51.

5. Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC, Nicholson KG. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect. 2011. 62:14–25.

6. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009. 339:b5106.

7. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindemann L, Carey E, Boak L, Gieschke R, Sacks S, Solsky J, Small I, Reddy D. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008. 31:1097–1114.

8. Seo ES, Park GH, Kim SM, Kim SW, Jung WS, Cho KS, Park YG, Lee CK, Kang C, Lee JY, Choi WY. Oseltamivir efficacy, side effects, and safety in children with influenza. Korean J Pediatr. 2010. 53:56–66.